Incidence and outcome of second malignancies in patients with chronic myeloid leukemia during treatment with tyrosine kinase inhibitors-Reference-Cited by-同舟云学术

Incidence and outcome of second malignancies in patients with chronic myeloid leukemia during treatment with tyrosine kinase inhibitors

Published:2018-05-30 Issue:7 Volume:35 Page:
ISSN:1357-0560
Container-title:Medical Oncology
language:en
Short-container-title:Med Oncol

Author:

Nakazato Tomonori^ORCID,Iriyama Noriyoshi,Tokuhira Michihide,Ishikawa Maho,Sato Eriko,Takaku Tomoiku,Sugimoto Kei-Ji,Fujita Hiroyuki,Fujioka Isao,Kimura Yuta,Aisa Yoshinobu,Iwanaga Eisaku,Asou Norio,Kizaki Masahiro,Hatta Yoshihiro,Komatsu Norio,Kawaguchi Tatsuya

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

http://link.springer.com/article/10.1007/s12032-018-1159-7/fulltext.html

Reference21 articles.

1. Gambacorti-Passerini C, Antolini L, Mahon FX, et al (2011) Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst 103: 553–561.

2. Hoglund M, Sandin F, Hellstrom K, et al. Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry. Blood. 2013;122:1284–1292.

3. Boggs DR. The pathogenesis and clinical patterns of blastic crisis of chronic myeloid leukemia. Semin Oncol. 1976;3:289–96.

4. Loriaux M, Deininger M. Clonal cytogenetic abnormalities in Philadelphia chromosome negative cells in chronic myeloid leukemia patients treated with imatinib. Leuk Lymphoma. 2004;45:2197–2203.

5. Verma D, Kantarjian H, Strom SS, et al. Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies. Blood. 2011;118:4353–4358.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Rare Case of Metastatic Small Cell Carcinoma of Lung in a Follow-Up Patient of Chronic Myeloid Leukemia on Imatinib Treatment;Cureus;2023-02-24

2. Secondary Ovarian Malignancy in an Imatinib treated Chronic Myeloid Leukemia Patient Diagnosed on Fluid Cytology;Clinical Cancer Investigation Journal;2023

3. Hodgkin Lymphoma as a Secondary Neoplasm During Therapy for Chronic Myeloid Leukaemia: Case Report and Review of the Literature;OncoTargets and Therapy;2021-04

4. Dual EGFR and ABL Tyrosine Kinase Inhibitor Treatment in a Patient with Concomitant EGFR-Mutated Lung Adenocarcinoma and BCR-ABL1-Positive CML;Case Reports in Oncological Medicine;2020-03-19

5. Potential role for second‑generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia harboring additional clonal chromosome abnormalities: A retrospective CML Cooperative Study Group analysis;Oncology Reports;2019-09-27